When it comes to biotech stocks, the author of today’s article notes that “An investment decision backed by careful scrutiny and analysis — of a company’s pipeline, collaborations, fundamentals, key make-or-break events and cash runway — can fetch disproportionate returns.” They proceed to highlight three biotech stocks that, with their respective pipelines and upcoming catalysts, have the potential to more than double from current levels. For more, CLICK HERE.
With Their Pipelines And Upcoming Catalysts, These 3 Biotech Stocks Have The Potential To More Than Double
- by RobH
